Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy

Statistics in Medicine

Volumn 36, Issue 29, 2017, Pages 4705-4718

  Rees, Jessica M B ^a   Wood, Angela M ^a   Burgess, Stephen ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

invalid instruments; Mendelian randomization; MR Egger; multivariable; pleiotropy

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR RISK; CAUSAL EFFECT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INTERMETHOD COMPARISON; MENDELIAN RANDOMIZATION ANALYSIS; MR-EGGER METHOD; MULTIVARIATE ANALYSIS; PLEIOTROPY; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; THEORY; CAUSALITY; COMPUTER SIMULATION; GENETIC PREDISPOSITION; GENETIC VARIATION; PROCEDURES; RISK FACTOR;

CAUSALITY; CHOLESTEROL, HDL; COMPUTER SIMULATION; CORONARY DISEASE; GENETIC PLEIOTROPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 85034812580     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.7492     Document Type: Article

References (34)

1. Smith GD, Ebrahim S. Mendelian randomization: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.
2. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-1163.
3. Sleiman PM, Grant SF. Mendelian randomization in the era of genomewide association studies. Clin Chem. 2010;56(5):723-728.
4. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5): 1497-1501.
5. Freeman G, Cowling BJ, Schooling CM. Power and sample size calculations for Mendelian randomization studies using one genetic instrument. Int J Epidemiol. 2013;42(4):1157-1163.
6. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol. 2013;42(4):1134-1144.
7. Burgess S, Thompson SG. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251-260.
8. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304-314.
9. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525.
10. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48(6):634-639.
11. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543-552.
12. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: Comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880-1906.
13. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(4):722-729.
14. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 2007;16(4):309-330.
15. Johnson T. Efficient calculation for multi-SNP genetic risk scores, The Comprehensive R Archive Network; 2013. http://cran.r-project.org/web/packages/gtx/vignettes/ashg2012.pdf. Accessed June 14, 2016.
16. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assoc. 1995;90(430):431-442.
17. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis withmultiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-665.
18. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: A comparison of methods. Stat Med. 1999;18(20):2693-2708.
19. Kolesár M, Chetty R, Friedman J, Glaeser E, Imbens G. Identification and inference with many invalid instruments. J Bus Econ Stat. 2015;33(4):474-484. http://doi.org.10.1080/07350015.2014.978175
20. Burgess S, Dudbridge F, Thompson SG. Re: “Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects". Am J Epidemiol. 2015;181(4):290-291.
21. Burgess S, Harshfield E. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: Lessons from the past and applications to the future. Curr Opin Endocrinol Diabetes. 2016;23(2):124-130.
22. Burgess S, Freitag DF, Khan H, Gorman DN, Thompson SG. Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions. PLoS One. 2014;9(10):e108891.
23. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-1283.
24. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345-1352.
25. Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121-1130.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
27. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
28. Fritz MS, Mackinnon DP. Required sample size to detect the mediated effect. Psychol Sci. 2007;18(3):233-239.
29. White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: A Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336.
30. Burgess S, Butterworth AS, Thompson JR. Beyond Mendelian randomization: How to interpret evidence of shared genetic predictors. J Clin Epidemiol. 2016;69:208-216.
31. Relton CL, Davey Smith G. Is epidemiology ready for epigenetics? Int J Epidemiol. 2012;41(1):5-9.
32. Suhre K, Raffler J, Kastenmuller G. Biochemical insights from population studies with genetics andmetabolomics. Arch Biochem Biophys. 2016;589:168-176.
33. Kastenmuller G, Raffler J, Gieger C, Suhre K. Genetics of human metabolism: An update. Hum Mol Genet. 2015;24(R1):R93-R101.
34. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961-1974.